(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Helios and Matheson Analytics, TherapeuticsMD, and Giga.

Rank Financial Asset Price Change Updated (EST)
1 Helios and Matheson Analytics (HMNY) 0.00 50% 2022-05-23 15:49:14
2 TherapeuticsMD (TXMD) 3.10 36.56% 2022-05-23 09:11:19
3 Giga (GIGA) 1.14 19.99% 2022-05-23 10:41:16
4 Castle Biosciences (CSTL) 21.65 10.29% 2022-05-23 09:06:12
5 Palo Alto Networks (PANW) 478.68 9.7% 2022-05-23 09:02:58
6 SmileDirectClub (SDC) 1.47 8.89% 2022-05-23 09:10:44
7 Second Sight Medical Products (EYES) 2.00 8.11% 2022-05-23 01:23:13
8 Hallador Energy Company (HNRG) 4.57 7.28% 2022-05-23 16:17:06
9 V.F. Corporation (VFC) 47.32 6.07% 2022-05-23 09:42:42
10 Forward Pharma A/S (FWP) 5.55 5.92% 2022-05-23 09:12:05

The three most active and biggest losers today are Ross Stores, NeuroMetrix, and Endo International plc.

Rank Financial Asset Price Change Updated (EST)
1 Ross Stores (ROST) 71.87 -22.47% 2022-05-23 13:37:39
2 NeuroMetrix (NURO) 4.31 -21.64% 2022-05-23 09:06:33
3 Endo International plc (ENDP) 0.46 -19.52% 2022-05-22 23:06:06
4 Burlington Stores (BURL) 150.71 -14.95% 2022-05-23 09:20:58
5 Evoke Pharma (EVOK) 0.26 -14.6% 2022-05-23 01:07:06
6 Deere & Company (DE) 313.31 -14.07% 2022-05-23 09:21:59
7 Novavax (NVAX) 53.42 -8.57% 2022-05-23 09:00:24
8 Canaan (CAN) 3.10 -8.28% 2022-05-23 04:37:16
9 U.S. Gold Corp (USAU) 4.03 -8.2% 2022-05-23 09:11:28
10 AMC (AMC) 12.03 -8.03% 2022-05-23 09:23:20

Most Active Winners today

1. Helios and Matheson Analytics (HMNY) – 50%

Helios and Matheson Analytics Inc. offers a variety of IT solutions for Fortune 1000 businesses and other US organizations. Services include service management for application value, development and integration as well as independent validation, infrastructure management and information management. The company’s clients are in many industries including healthcare, banking and financial services. The firm was previously known as Helios and Matheson Information Technology Inc. and it changed its name in May 2013 to Helios and Matheson Analytics Inc. The company was established in 1982 and has its headquarters in New York. Helios and Matheson Analytics Inc. filed, along with affiliates, a voluntary petition to liquidate under Chapter 7 at the U.S. Bankruptcy Court, Southern District of New York on January 28, 2020.

NASDAQ ended the session with Helios and Matheson Analytics jumping 50% to $0.00 on Monday while NASDAQ slid 0.3% to $11,354.62.

Volume

Today’s last reported volume for Helios and Matheson Analytics is 16843 which is 94.66% below its average volume of 315702.

Helios and Matheson Analytics’s last close was $0.00, 94.29% below its 52-week high of $0.00.

Helios and Matheson Analytics’s Sales

Helios and Matheson Analytics’s sales growth is 923.6% for the ongoing quarter and 329.5% for the next.

Helios and Matheson Analytics’s Revenue

Year-on-year quarterly revenue growth grew by 6268.3%, now sitting on 205.08M for the twelve trailing months.

Helios and Matheson Analytics’s Stock Yearly Top and Bottom Value

Helios and Matheson Analytics’s stock is valued at $0.00 at 17:32 EST, below its 52-week low of $0.00.

Helios and Matheson Analytics’s Moving Average

Helios and Matheson Analytics’s value is below its 50-day moving average of $0.00 and under its 200-day moving average of $0.00.

More news about Helios and Matheson Analytics.

2. TherapeuticsMD (TXMD) – 36.56%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company’s clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under its vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD jumping 36.56% to $3.10 on Monday, after two sequential sessions in a row of gains. NASDAQ fell 0.3% to $11,354.62, after three sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for TherapeuticsMD is 22132200 which is 3339.73% above its average volume of 643428.

TherapeuticsMD’s last close was $3.10, 12.73% higher than its 52-week high of $2.75.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is 33.7% for the present quarter and 29.3% for the next. The company’s growth estimates for the ongoing quarter and the next is 16.7% and 40%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be oversold (<=20).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $3.10 at 17:32 EST, way higher than its 52-week high of $2.75.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s worth is way higher than its 50-day moving average of $0.66 and way higher than its 200-day moving average of $1.00.

More news about TherapeuticsMD.

3. Giga (GIGA) – 19.99%

Giga-tronics Incorporated and its subsidiaries develop and produce electronic equipment for military and airborne operations in the United States as well as internationally. The company operates in two segments: Microsource and the Giga-tronics Division. It also produces microwave integrated parts, MIC components and Band Reject filters for RADAR/EW. These are used to solve interference issues in RADAR/EW applications. It also designs, produces, and markets functional testing products to test RADAR/EW electronics in the defense electronic market. It serves the prime defense contractors as well as research institutes and the Armed Services. Giga-tronics Incorporated, which was founded in 1980, is based in Dublin (California).

NASDAQ ended the session with Giga jumping 19.99% to $1.14 on Monday while NASDAQ fell 0.3% to $11,354.62.

Volume

Today’s last reported volume for Giga is 2947 which is 94.13% above its average volume of 1518.

Giga’s last close was $1.14, 73.3% below its 52-week high of $4.27.

Giga’s Revenue

Year-on-year quarterly revenue growth declined by 51.7%, now sitting on 10.32M for the twelve trailing months.

Giga’s Stock Yearly Top and Bottom Value

Giga’s stock is valued at $1.14 at 17:32 EST, way under its 52-week high of $4.27 and way higher than its 52-week low of $0.85.

Giga’s Moving Average

Giga’s value is way under its 50-day moving average of $2.00 and way below its 200-day moving average of $2.81.

More news about Giga.

4. Castle Biosciences (CSTL) – 10.29%

Castle Biosciences, Inc., which is a company that develops and markets diagnostic and prognostic tools for skin cancers, has reached commercial stage. DecisionDx–Melanoma is the company’s flagship product. This multi-gene expression profil (GEP test) identifies stage I/I patients who are at highest risk for metastasis using biological information from 31 tumor tissues. DecisionDx-UM is a GEP proprietary test which predicts metastasis risk for patients suffering from uveal melanoma. There are also two proprietary products at late stage that address cutaneous squamous cells carcinoma and suspicious pigmented lesion, both indications of high clinical need in dermatological. The company offers testing services via physicians, nurse practitioners, and physician assistants. It was established in Texas in 2007.

NASDAQ ended the session with Castle Biosciences rising 10.29% to $21.65 on Monday while NASDAQ dropped 0.3% to $11,354.62.

Volume

Today’s last reported volume for Castle Biosciences is 411532 which is 21.37% above its average volume of 339049.

Castle Biosciences’s last close was $21.65, 72.57% below its 52-week high of $78.92.

The company’s growth estimates for the ongoing quarter and the next is a negative 114.3% and a negative 68.1%, respectively.

Castle Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 44.7%, now sitting on 94.08M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Castle Biosciences’s stock is considered to be oversold (<=20).

Castle Biosciences’s Stock Yearly Top and Bottom Value

Castle Biosciences’s stock is valued at $21.65 at 17:32 EST, way under its 52-week high of $78.92 and way above its 52-week low of $17.01.

Castle Biosciences’s Moving Average

Castle Biosciences’s value is way under its 50-day moving average of $30.67 and way under its 200-day moving average of $47.89.

More news about Castle Biosciences.

5. Palo Alto Networks (PANW) – 9.7%

Palo Alto Networks, Inc. offers cybersecurity platform solutions around the world. It offers software and firewall appliances; Panorama is a security management system that allows you to control appliances and software on your network. Virtual system upgrades are also available. These can be used as an extension of the physical system capacity. The company also provides subscription services in the areas of threat prevention and uniform resource locator filtering. It offers malware and persistent threats, mobile and laptop protection, firewall and threat intelligence. The company also offers professional services such as architecture design, planning, configuration and migration. It also provides online and in-classroom training services as well support services. Palo Alto Networks, Inc. offers its services and products through channel partners, medium- to large businesses, service providers, government agencies, and individuals working in various sectors, such as education, energy, financial, government, healthcare, media, manufacturing, the public sector, and telecommunications. Santa Clara is the headquarters of this company, which was established in 2005.

NYSE ended the session with Palo Alto Networks rising 9.7% to $478.68 on Monday while NYSE rose 0.3% to $15,080.98.

Volume

Today’s last reported volume for Palo Alto Networks is 5900050 which is 219.5% above its average volume of 1846600.

Palo Alto Networks’s last close was $478.68, 25.31% below its 52-week high of $640.90.

The company’s growth estimates for the ongoing quarter and the next is 21.7% and 38.8%, respectively.

Palo Alto Networks’s Revenue

Year-on-year quarterly revenue growth grew by 29.5%, now sitting on 4.86B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Palo Alto Networks’s stock is considered to be oversold (<=20).

Palo Alto Networks’s Stock Yearly Top and Bottom Value

Palo Alto Networks’s stock is valued at $478.68 at 17:32 EST, way under its 52-week high of $640.90 and way higher than its 52-week low of $350.96.

Palo Alto Networks’s Moving Average

Palo Alto Networks’s worth is way under its 50-day moving average of $566.36 and below its 200-day moving average of $515.89.

More news about Palo Alto Networks.

6. SmileDirectClub (SDC) – 8.89%

SmileDirectClub, Inc. provides a teledentistry service that allows members to receive a custom clear aligner therapy treatment both in the United States as well as internationally. It manages all aspects of the treatment process from marketing to fulfillment and treatment by a dentist. The company offers retainers, aligners and impression kits as well as whitening gels. It was established in 2014 in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub jumping 8.89% to $1.47 on Monday while NASDAQ slid 0.3% to $11,354.62.

Volume

Today’s last reported volume for SmileDirectClub is 2140160 which is 39.91% below its average volume of 3562100.

SmileDirectClub’s last close was $1.47, 86.66% under its 52-week high of $11.02.

SmileDirectClub’s Sales

SmileDirectClub’s sales growth is a negative 29.8% for the current quarter and a decline by 20.7% for the next. The company’s growth estimates for the present quarter is a negative 177.8% and positive 32% for the next.

SmileDirectClub’s Revenue

Year-on-year quarterly revenue growth declined by 18.3%, now sitting on 695.88M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

SmileDirectClub’s stock is considered to be oversold (<=20).

SmileDirectClub’s Stock Yearly Top and Bottom Value

SmileDirectClub’s stock is valued at $1.47 at 17:32 EST, way under its 52-week high of $11.02 and way higher than its 52-week low of $1.19.

SmileDirectClub’s Moving Average

SmileDirectClub’s worth is way below its 50-day moving average of $2.19 and way under its 200-day moving average of $3.61.

More news about SmileDirectClub.

7. Second Sight Medical Products (EYES) – 8.11%

Second Sight Medical Products, Inc. designs, produces, and sells implantable vision prosthetics. These devices are designed to provide artificial sight to the blind. The company develops technology to help the sight impaired population. Orion Visual Cortical Prosthesis System is an implanted cortical stimulation system that provides artificial vision for blind individuals. It can be used to treat glaucoma and other conditions such as diabetic retinopathy or optic nerve injury, disease, eye injury, and glaucoma. It was established in 1998 in Sylmar in California.

NASDAQ ended the session with Second Sight Medical Products jumping 8.11% to $2.00 on Monday while NASDAQ dropped 0.3% to $11,354.62.

Volume

Today’s last reported volume for Second Sight Medical Products is 602985 which is 90.87% above its average volume of 315908.

Second Sight Medical Products’s last close was $2.00, 73.82% under its 52-week high of $7.64.

Second Sight Medical Products’s Stock Yearly Top and Bottom Value

Second Sight Medical Products’s stock is valued at $2.00 at 17:32 EST, way below its 52-week high of $7.64 and way above its 52-week low of $1.14.

Second Sight Medical Products’s Moving Average

Second Sight Medical Products’s value is way higher than its 50-day moving average of $1.46 and below its 200-day moving average of $2.17.

More news about Second Sight Medical Products.

8. Hallador Energy Company (HNRG) – 7.28%

Through its subsidiaries, Hallador Energy Company engages in steam coal production in the Illinois basin to power the electricity generation industry. It owns the Oaktown 1 & Oaktown 2 underground mining operations in Oaktown, Indiana, and Ace in the Hole, which is located in Clay City, Indiana. The company is involved in Indiana’s gas exploration. It was established in Terre Haute in Indiana in 1949.

NASDAQ ended the session with Hallador Energy Company jumping 7.28% to $4.57 on Monday while NASDAQ fell 0.3% to $11,354.62.

Volume

Today’s last reported volume for Hallador Energy Company is 230413 which is 59.82% below its average volume of 573565.

Hallador Energy Company’s last close was $4.26, 30.96% below its 52-week high of $6.17.

Hallador Energy Company’s Revenue

Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 247.67M for the twelve trailing months.

Hallador Energy Company’s Stock Yearly Top and Bottom Value

Hallador Energy Company’s stock is valued at $4.57 at 17:32 EST, way below its 52-week high of $6.17 and way above its 52-week low of $1.99.

Hallador Energy Company’s Moving Average

Hallador Energy Company’s value is way above its 50-day moving average of $4.08 and way higher than its 200-day moving average of $3.09.

More news about Hallador Energy Company.

9. V.F. Corporation (VFC) – 6.07%

V.F. V.F. Corporation is engaged in design, manufacturing, procurement, marketing and distribution of lifestyle products, including footwear and apparel for children and adults in Europe and Americas. The company operates in four areas: Work, Outdoor and Active. It offers casual, outdoor and merino wool apparel, equipment, accessories, as well as performance-based youth culture/action sport-inspired footwear. The company also sells handbags and luggage. The company sells its products under the Timberland and Timberland brands, as well as Smartwool, Altra. Vans, Kipling. Eagle Creek. Dickies. Timberland PRO. It sells products to specialty shops, department stores and national chains as well as mass merchants. The company also sells direct-to consumer operations including retail, concession and online stores. Corporation was established in Greenwood Village in Colorado in 1899.

NYSE ended the session with V.F. Corporation jumping 6.07% to $47.32 on Monday, after three successive sessions in a row of gains. NYSE rose 0.3% to $15,080.98, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for V.F. Corporation is 8950520 which is 160.87% above its average volume of 3431010.

V.F. Corporation’s last close was $47.32, 47.88% under its 52-week high of $90.79.

The company’s growth estimates for the current quarter and the next is 71.6% and 40.9%, respectively.

V.F. Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 103.9%, now sitting on 10.36B for the twelve trailing months.

V.F. Corporation’s Stock Yearly Top and Bottom Value

V.F. Corporation’s stock is valued at $47.32 at 17:32 EST, way under its 52-week low of $65.34.

V.F. Corporation’s Moving Average

V.F. Corporation’s worth is way under its 50-day moving average of $73.57 and way below its 200-day moving average of $78.25.

More news about V.F. Corporation.

10. Forward Pharma A/S (FWP) – 5.92%

Forward Pharma A/S doesn’t have any significant operations. It was a biopharmaceutical firm that developed a proprietary dimethyl fumarate formulation for neuro-inflammatory indications. It was founded in Copenhagen, Denmark in 2005.

NASDAQ ended the session with Forward Pharma A/S jumping 5.92% to $5.55 on Monday while NASDAQ fell 0.3% to $11,354.62.

Volume

Today’s last reported volume for Forward Pharma A/S is 2976 which is 69.07% below its average volume of 9624.

Forward Pharma A/S’s last close was $5.55, 72.67% below its 52-week high of $20.31.

Forward Pharma A/S’s Stock Yearly Top and Bottom Value

Forward Pharma A/S’s stock is valued at $5.55 at 17:32 EST, way below its 52-week high of $20.31 and way higher than its 52-week low of $4.86.

Forward Pharma A/S’s Moving Average

Forward Pharma A/S’s worth is under its 50-day moving average of $5.68 and way under its 200-day moving average of $6.22.

More news about Forward Pharma A/S.

Most Active Losers Today

1. Ross Stores (ROST) – -22.47%

Ross Stores, Inc., along with its affiliates, operate off-price home fashion and apparel stores under the Ross Dress for Less brands and dd’s DISCOUNTS. The company’s retail stores sell mainly apparel, accessories and footwear. Ross Dress for Less is a company store that sells its products in specialty and department stores. Its Ross Dress for Less stores are primarily for middle-income households. dd’s DISCOUNTS stores sell their products in department stores and discount shops at regular prices for customers with moderate income. It had approximately 1,850 home and fashion shops and apparel at reduced prices in forty states and the District of Columbia as of February 3, 2021. It was established in 1982 in Dublin, California.

NASDAQ ended the session with Ross Stores dropping 22.47% to $71.87 on Monday while NASDAQ dropped 0.3% to $11,354.62.

Volume

Today’s last reported volume for Ross Stores is 34575500 which is 855.84% above its average volume of 3617280.

Ross Stores’s last close was $71.87, 43.67% under its 52-week high of $127.58.

The company’s growth estimates for the present quarter and the next is a negative 25.4% and a negative 2.9%, respectively.

Ross Stores’s Revenue

Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 18.92B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Ross Stores’s stock is considered to be overbought (>=80).

Ross Stores’s Stock Yearly Top and Bottom Value

Ross Stores’s stock is valued at $71.87 at 17:32 EST, way below its 52-week high of $127.58 and above its 52-week low of $69.75.

Ross Stores’s Moving Average

Ross Stores’s value is way under its 50-day moving average of $95.46 and way below its 200-day moving average of $105.46.

More news about Ross Stores.

2. NeuroMetrix (NURO) – -21.64%

NeuroMetrix, Inc., is a healthcare company that develops and markets products to detect, diagnose, and monitor peripheral nerve and spine cord disorders. It develops neuro-stimulation therapy devices for wearable use and points-of-care diagnostic tests for neuropathy to treat chronic conditions such as diabetes, chronic pain and sleep disorders. The company’s most popular products are Quell which is a wearable device that provides relief from chronic, intractable, pain. This includes nerve pain caused by diabetes or lower back pain; DPNCheck which can be used to assess systemic neuropathies such as diabetic peripheral nerve neuropathy. ADVANCE, an online platform, allows for traditional nerve conduction studies to be performed; and SENSUS. A pain therapy device that uses transcutaneous electrical nerve stimulation to relieve chronic, intractable, pain. It sells its products to customers, retailers, TV promotors, doctors, nurses, health professionals, managed care organisations, physicians, surgeons, physical medicine and rehabilitation centres, primary care, orthopedic, hand and neurosurgeons. The company operates across the United States and Mexico, as well as in Europe, Japan China, China, Middle East, Mexico, and China. GlaxoSmithKline has been a strategic partner of the company. NeuroMetrix, Inc., was established in 1996. It is located in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix dropping 21.64% to $4.31 on Monday, following the last session’s downward trend. NASDAQ dropped 0.3% to $11,354.62, after three consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for NeuroMetrix is 9017290 which is 474.03% above its average volume of 1570850.

NeuroMetrix’s last close was $4.31, 88.88% below its 52-week high of $38.75.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth grew by 6.8%, now sitting on 8.4M for the twelve trailing months.

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $4.31 at 17:32 EST, way below its 52-week high of $38.75 and way higher than its 52-week low of $2.70.

NeuroMetrix’s Moving Average

NeuroMetrix’s worth is way higher than its 50-day moving average of $3.77 and way below its 200-day moving average of $6.68.

More news about NeuroMetrix.

3. Endo International plc (ENDP) – -19.52%

Endo International plc is a specialist pharmaceutical company that manufactures and markets generic and brand pharmaceuticals both in the United States as well as internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren’s contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. Its Sterile Injectables division manufactures VASOSTRICT and ADRENALIN. The Generic Pharmaceuticals segment provides solid oral extended-release and solid oral immediate release liquids as well as semi-solids patches, powders, sprays, ophthalmic drugs, and powders. International Pharmaceuticals is a company segment that offers specialty pharmaceutical products for various therapeutic areas, including pain, attention deficit hyperactivity disorder (ADHD), women’s health and oncology. It sells generic and branded drugs to doctors, specialists, pharmacies and government agencies. Endo International plc, which was established in Dublin in Ireland in 1920.

NASDAQ ended the session with Endo International plc sliding 19.52% to $0.46 on Monday while NASDAQ dropped 0.3% to $11,354.62.

Volume

Today’s last reported volume for Endo International plc is 26845500 which is 278.64% above its average volume of 7089830.

Endo International plc’s last close was $0.47, 93.35% below its 52-week high of $7.07.

Endo International plc’s Sales

Endo International plc’s sales growth is a negative 9.1% for the ongoing quarter and a decline by 19.9% for the next. The company’s growth estimates for the present quarter and the next is a negative 39.7% and a negative 121.5%, respectively.

Endo International plc’s Revenue

Year-on-year quarterly revenue growth declined by 9.1%, now sitting on 2.93B for the twelve trailing months.

Endo International plc’s Stock Yearly Top and Bottom Value

Endo International plc’s stock is valued at $0.46 at 17:32 EST, way under its 52-week high of $7.07 and way higher than its 52-week low of $0.36.

Endo International plc’s Moving Average

Endo International plc’s worth is way below its 50-day moving average of $2.05 and way under its 200-day moving average of $3.38.

More news about Endo International plc.

4. Burlington Stores (BURL) – -14.95%

Burlington Stores, Inc. is a US retailer for branded apparel. It offers fashion-oriented merchandise such as women’s ready to wear apparel, accessories and footwear as well as youth clothing, coats and toys. Burlington Stores is the company’s main brand. It has 736 locations in 45 states and Puerto Rico. Burlington is the headquarters of this company, which was established in 1972.

NYSE ended the session with Burlington Stores dropping 14.95% to $150.71 on Monday, after four consecutive sessions in a row of losses. NYSE rose 0.3% to $15,080.98, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Burlington Stores is 4005790 which is 277.45% above its average volume of 1061250.

Burlington Stores’s last close was $150.71, 57.82% under its 52-week high of $357.34.

Burlington Stores’s Sales

Burlington Stores’s sales growth is 33.9% for the current quarter and 19.5% for the next. The company’s growth estimates for the current quarter and the next is 344.8% and 39.3%, respectively.

Burlington Stores’s Revenue

Year-on-year quarterly revenue growth grew by 119%, now sitting on 8.35B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Burlington Stores’s stock is considered to be overbought (>=80).

Burlington Stores’s Stock Yearly Top and Bottom Value

Burlington Stores’s stock is valued at $150.71 at 17:33 EST, way below its 52-week low of $229.53.

Burlington Stores’s Moving Average

Burlington Stores’s worth is way under its 50-day moving average of $280.61 and way below its 200-day moving average of $307.57.

More news about Burlington Stores.

5. Evoke Pharma (EVOK) – -14.6%

Evoke Pharma, Inc. is a specialty pharmaceutical firm that focuses primarily on developing and marketing drugs to treat gastroenterological diseases and disorders. Gimoti is a nasal spray containing metoclopramide that treats symptoms of acute and recurrent diabetes gastroparesis. It has successfully completed its Phase III clinical trials. It sells its products to internal medicine specialists and primary care doctors, as well as select health care professionals. Evoke Pharma, Inc., was founded in 2007 in Solana Beach, California.

NASDAQ ended the session with Evoke Pharma falling 14.6% to $0.26 on Monday while NASDAQ fell 0.3% to $11,354.62.

Volume

Today’s last reported volume for Evoke Pharma is 2524150 which is 48.35% below its average volume of 4887190.

Evoke Pharma’s last close was $0.26, 83.8% below its 52-week high of $1.58.

Evoke Pharma’s Sales

Evoke Pharma’s sales growth is 144.7% for the ongoing quarter and a decline by 19.4% for the next. The company’s growth estimates for the present quarter and the next is 28.6% and 16.7%, respectively.

Evoke Pharma’s Revenue

Year-on-year quarterly revenue growth grew by 362.7%, now sitting on 1.95M for the twelve trailing months.

Evoke Pharma’s Stock Yearly Top and Bottom Value

Evoke Pharma’s stock is valued at $0.26 at 17:33 EST, way under its 52-week high of $1.58 and way higher than its 52-week low of $0.23.

Evoke Pharma’s Moving Average

Evoke Pharma’s worth is way under its 50-day moving average of $0.44 and way under its 200-day moving average of $0.78.

More news about Evoke Pharma.

6. Deere & Company (DE) – -14.07%

Deere & Company and its affiliates manufacture and distribute equipment around the world. It operates in three main segments, Agriculture and Turf; Construction and Forestry; and Financial Services. The company operates through three segments: Agriculture and Turf, Construction and Forestry, and Financial Services. Construction and Forestry offers machines and parts for construction, earthmoving and road building. Financial Services finances the sale and leasing of agriculture, turf and construction equipment. The Financial Services segment offers wholesale financing for dealers of these equipment, extended warranties and finance retail revolving charges accounts. It was established in Moline in Illinois in 1837.

NYSE ended the session with Deere & Company sliding 14.07% to $313.31 on Monday, after five successive sessions in a row of losses. NYSE jumped 0.3% to $15,080.98, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Deere & Company is 8814280 which is 306.65% above its average volume of 2167530.

Deere & Company’s last close was $313.31, 21.74% under its 52-week high of $400.34.

The company’s growth estimates for the present quarter and the next is 71.1% and 15.2%, respectively.

Deere & Company’s Revenue

Year-on-year quarterly revenue growth grew by 28.9%, now sitting on 42.4B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Deere & Company’s stock is considered to be overbought (>=80).

Deere & Company’s Stock Yearly Top and Bottom Value

Deere & Company’s stock is valued at $313.31 at 17:33 EST, way under its 52-week high of $400.34 and way higher than its 52-week low of $252.51.

Deere & Company’s Moving Average

Deere & Company’s worth is way under its 50-day moving average of $348.74 and way under its 200-day moving average of $359.69.

More news about Deere & Company.

7. Novavax (NVAX) – -8.57%

Novavax, Inc., along with Novavax AB, a subsidiary, focuses on developing, commercializing and marketing vaccines that prevent serious infections. ResVax is a candidate for a vaccine against respiratory syncytial viruses (RSV), fusion (F), protein nanoparticles. It’s currently in Phase III clinical trials to prevent RSV infection in infants through maternal immunization. NanoFlu, an older adult treatment, is also in Phase III clinical trials. Matrix-M is the company’s main adjuvant. It is used to increase the immune system attack against microorganisms and to immunize with lower levels of antigen. RSV F vaccine is being developed by the company for elderly (60+) and healthy children (6 months to 5 years old). Phase II clinical trials are ongoing. Phase I clinical trials are underway for both. It is also developing nanoparticle vaccine candidates to be used in clinic testing for the ebola virus. The company also has a COVID-19 vaccine being developed for the coronavirus, which causes symptoms similar to pneumonia. This is currently in preclinical phase. Novavax, Inc., was established in 1987. It is located in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax sliding 8.57% to $53.42 on Monday, following the last session’s downward trend. NASDAQ fell 0.3% to $11,354.62, after three consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Novavax is 7205660 which is 53.11% above its average volume of 4706130.

Novavax’s last close was $53.42, 80.77% below its 52-week high of $277.80.

The company’s growth estimates for the ongoing quarter and the next is 210.7% and 254.1%, respectively.

Novavax’s Revenue

Year-on-year quarterly revenue growth declined by 20.5%, now sitting on 1.15B for the twelve trailing months.

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $53.42 at 17:33 EST, way below its 52-week high of $277.80 and way higher than its 52-week low of $41.33.

Novavax’s Moving Average

Novavax’s worth is way below its 50-day moving average of $61.76 and way below its 200-day moving average of $138.18.

Previous days news about Novavax

  • Novavax stock drops after bofa's bearish call. According to MarketWatch on Friday, 20 May, "Resolution on approvability in flu, RSV, and malaria are also still open questions, with these markets becoming increasingly crowded and emerging competitor data looking strong relative to what Novavax has shown.", "Stranahan initiated coverage of Novavax at underperform and with a $35 stock price target, which implies about 34% downside from current levels. "

More news about Novavax.

8. Canaan (CAN) – -8.28%

Canaan Inc. is involved in research, development, and sales of integrated circuits (IC) final product products. It integrates IC products to bitcoin mining and other related components primarily from the People’s Republic of China. The company is involved in system product assembly, supply chain management and distribution. Northern Data AG has been a strategic partner of the company in areas such as artificial intelligence, blockchain technology and datacenter operation. Hangzhou is the location of this company, which was established in 2013.

NASDAQ ended the session with Canaan falling 8.28% to $3.10 on Monday, following the last session’s downward trend. NASDAQ slid 0.3% to $11,354.62, after three consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for Canaan is 5021900 which is 16.85% below its average volume of 6040150.

Canaan’s last close was $3.10, 73.04% under its 52-week high of $11.50.

Canaan’s Revenue

Year-on-year quarterly revenue growth grew by 5611.9%, now sitting on 4.99B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Canaan’s stock is considered to be overbought (>=80).

Canaan’s Stock Yearly Top and Bottom Value

Canaan’s stock is valued at $3.10 at 17:33 EST, way below its 52-week high of $11.50 and way higher than its 52-week low of $2.56.

Canaan’s Moving Average

Canaan’s worth is way under its 50-day moving average of $4.61 and way under its 200-day moving average of $6.42.

More news about Canaan.

9. U.S. Gold Corp (USAU) – -8.2%

NASDAQ ended the session with U.S. Gold Corp falling 8.2% to $4.03 on Monday, after two sequential sessions in a row of losses. NASDAQ dropped 0.3% to $11,354.62, after three sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for U.S. Gold Corp is 27089 which is 68.6% below its average volume of 86286.

U.S. Gold Corp’s last close was $4.03, 76.84% below its 52-week high of $17.40.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

U.S. Gold Corp’s stock is considered to be overbought (>=80).

U.S. Gold Corp’s Stock Yearly Top and Bottom Value

U.S. Gold Corp’s stock is valued at $4.03 at 17:33 EST, way below its 52-week low of $8.50.

U.S. Gold Corp’s Moving Average

U.S. Gold Corp’s value is way under its 50-day moving average of $10.13 and way below its 200-day moving average of $10.50.

More news about U.S. Gold Corp.

10. AMC (AMC) – -8.03%

AMC Entertainment Holdings, Inc., via its subsidiaries, is involved in theatrical exhibitions. It owns or operates theatres. It operated around 1,000 theaters in America and over 11,000 worldwide screens as of March 17, 2020. It was established in 1920 in Leawood Kansas. AMC Entertainment Holdings, Inc., is a subsidiary Dalian Wanda Group Co., Ltd.

NYSE ended the session with AMC sliding 8.03% to $12.03 on Monday while NYSE rose 0.3% to $15,080.98.

Volume

Today’s last reported volume for AMC is 41066800 which is 17.75% below its average volume of 49933700.

AMC’s last close was $12.03, 83.43% below its 52-week high of $72.62.

News about AMC today

  • Despite Friday's 8% collapse, AMC stock advanced last week. According to today’s article on FXStreet, "Attendance numbers for the latest release are seized on by AMC apes, and indeed attendances have been recovering impressively. ", "Yes, revenues are growing and recovering strongly, but AMC just has too much debt and is really going to struggle to repay it in theyears ahead. "

The company’s growth estimates for the current quarter and the next is 93.6% and 96.6%, respectively.

AMC’s Revenue

Year-on-year quarterly revenue growth declined by 84.2%, now sitting on 449.2M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

AMC’s stock is considered to be overbought (>=80).

AMC’s Stock Yearly Top and Bottom Value

AMC’s stock is valued at $12.03 at 17:33 EST, way under its 52-week high of $72.62 and way higher than its 52-week low of $1.91.

AMC’s Moving Average

AMC’s worth is way below its 50-day moving average of $37.41 and way under its 200-day moving average of $31.84.

Previous days news about AMC

  • AMC stock should get short-term pop, but long term it is set to drop. According to FXStreet on Friday, 20 May, "National CineMedia is a good fit for AMC as the company provides advertising and marketing in cinema theatres. ", "Retail investors have taken in some harsh lessons this year as the stock market turns south and we still feel more pain is on its wayfor long-term AMC holders."

More news about AMC.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here